A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. Supplementary Figures and Tables
收藏官方服务：
资源简介：
Supplementary Figures 1-7. Supplementary Tables 1-5
补充图（Supplementary Figures）1至7、补充表（Supplementary Tables）1至5
创建时间：
2024-01-31
